In patients with small failed surgical bioprostheses, valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) was associated with “extremely low” rates of periprocedural complications and 30-day adverse events regardless of the type of transcatheter heart valve used, according to a small randomized controlled trial.